NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 293)
Posted On: 10/29/2018 4:40:36 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Holds Robust IP Portfolio Protecting DehydraTECH Technology
Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) drug delivery platform DehydraTECH employs its patented technology to improve bio-absorption and bioavailability of active ingredients while covering unpleasant tastes. A recent article discussing the company’s technology reads, “Lexaria’s disruptive DehydraTECH drug delivery platform is protected by a robust suite of patents granted or pending worldwide. It has been proven effective in multiple international studies in greatly assisting rapidity and quantity of absorption of a range of lipophilic (i.e., fat-soluble), bioactive molecules – such as those contained in cannabinoids (CBD), nicotine, non-steroidal anti-inflammatory drugs (NSAIDs) and other molecules. DehydraTECH offers a healthier, oral ingestion alternative to other delivery methods, such as smoking, which has known negative consequences, to quickly and effectively deliver the bioactive substances that cannabis and nicotine consumers are seeking, as Lexaria points out in detail on its website.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) drug delivery platform DehydraTECH employs its patented technology to improve bio-absorption and bioavailability of active ingredients while covering unpleasant tastes. A recent article discussing the company’s technology reads, “Lexaria’s disruptive DehydraTECH drug delivery platform is protected by a robust suite of patents granted or pending worldwide. It has been proven effective in multiple international studies in greatly assisting rapidity and quantity of absorption of a range of lipophilic (i.e., fat-soluble), bioactive molecules – such as those contained in cannabinoids (CBD), nicotine, non-steroidal anti-inflammatory drugs (NSAIDs) and other molecules. DehydraTECH offers a healthier, oral ingestion alternative to other delivery methods, such as smoking, which has known negative consequences, to quickly and effectively deliver the bioactive substances that cannabis and nicotine consumers are seeking, as Lexaria points out in detail on its website.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼